Nizozemska - nizozemski - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

eureco-pharma b.v. boelewerf 2 2987 vd ridderkerk - cefotaxim natrium samenstelling overeenkomend met ; cefotaxim - poeder voor oplossing voor injectie of infusie - geen hulpstoffen - cefotaxime

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires théa - cefuroximnatrium 52 mg - eq. cefuroxim 50 mg - poeder voor oplossing voor injectie - 50 mg - cefuroximnatrium 52 mg - cefuroxime

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratoires delbert s.a.s. - clavulaanzuur 200 mg; amoxicillinenatrium - eq. amoxicilline 1000 mg - poeder voor oplossing voor injectie/infusie - 1000 mg - 200 mg - clavulaanzuur 200 mg; amoxicillinenatrium - amoxicillin and enzyme inhibitor

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - kaliumclavulanaat - eq. clavulaanzuur 100 mg; amoxicillinenatrium - eq. amoxicilline 1000 mg - poeder voor oplossing voor injectie/infusie - 1000 mg - 100 mg - kaliumclavulanaat; amoxicillinenatrium - amoxicillin and enzyme inhibitor

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurocept international b.v. - cefazolinenatrium - eq. cefazoline 1 g - poeder voor oplossing voor injectie - 1 g - cefazolinenatrium - cefazolin

Belgija - nizozemski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eurocept international b.v. - cefazolinenatrium - eq. cefazoline 1 g - poeder en oplosmiddel voor oplossing voor injectie - cefazolinenatrium - cefazolin; n01bb52 lidocaine, combinations

Europska Unija - nizozemski - EMA (European Medicines Agency)

sanofi winthrop industrie - insuline aspart - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Europska Unija - nizozemski - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - multiple myeloma - antineoplastische middelen - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Europska Unija - nizozemski - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastro-intestinale stromale tumoren - andere antineoplastische middelen, proteïne kinase remmers - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Europska Unija - nizozemski - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningokokken - vaccins - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y. the use of this vaccine should be in accordance with available official recommendations.